Response to Comments: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia

This policy (A59344) documents the response to comments for MolDX Local Coverage Determination L39256 regarding molecular testing for upper gastrointestinal metaplasia, dysplasia, and neoplasia. The comment period ran from 2022-03-31 to 2022-05-14; the notice period begins 2023-03-30 and the LCD becomes effective 2023-05-14. For specific coverage criteria (indications, limitations, documentation, and frequency), refer to LCD L39256.

"This document is a response to comments for MolDX Local Coverage Determination L39256 (Molecular testing for detection of upper gastrointestinal metaplasia, dysplasia, and neoplasia); comment perio..."

Sign up to see full coverage criteria, indications, and limitations.